BUY
Very high-quality company. There are some issues around their stent business, but long-term it doesn't get much better. Trades at historically low multiple of about 15X.
BUY
Market has been excessively negative. Their core money management business, asset management business, investment banking business, high net worth and brokerage businesses are all in very good shape. Trades at less than 10X next year's earnings. Close to 1.5X book.
DON'T BUY
Has had a spectacular quarter, but in his opinion it is too much in favour. Trades at about 2.3X book, which is too high for him.
BUY
Has gone down too much. Big losses in their mortgage portfolio, but fundamentally it is a short-term issue. Next year they will still have very strong global retail banking, global credit card businesses and global commercial banking businesses. Their investment banking and equities business is in good shape. Trading at about 8X next year's earnings.
DON'T BUY
A wonderful company and they have made a lot of money for themselves. He doesn't like the model of taking a private equity firm public and trying to capitalize those performance and money management fees. There is just too much incentive now to grow assets, which is not going to be in the best interests of those underlying limited partners. Believes the right model for them is a partnership.
BUY
Produce Transformers that are used in different industries. Greatest success of late has been in the wind power and mining industries. Recently did an acquisition to expand their product offering. Has been in his watch list. Very strong management with good opportunities.
COMMENT
A fairly early stage public company. Didn't pass his metrics on earnings and profitability, but seemed to be doing okay in their little niche. The real challenge is that it is a niche brewery and how they would grow themselves. Deserves to be on a watch list.
DON'T BUY
Had some significant top line growth, but had some significant write offs relating to the acquisition they did. They are hinging a lot of their business on some major US contracts. At this price, it is worth watching.
HOLD
Recently guided that 08 revenue would probably double. The stock has responded favourably to it. When the stock moves that strong, you have to sit back and let it settle down. Has a very interesting opportunity in the whole affinity program.
DON'T BUY
They market a natural sweetener, which doesn't give the insulin response that sugar does. Available in health food stores. Worth watching.
TOP PICK
Supply airborne surveys for primarily the mining industry. Has had some very good growth. Recently did an acquisition that expanded their technology from a rotary type business to a fixed wing business. Leading edge technology. Very profitable. Last quarter exceeded his expectations. He is looking for $47 million in sales next year with $.18 in earnings. Trades at about 19X forward earnings.
TOP PICK
Has been a growth story based on supplying software to the mining industry to help them with working with smaller workforces and maximize the mineral deposits. Cash flow positive. Good top line growth. Made an acquisition in the last year to help diversify their business.
WAIT
Flight data recorder, but much more sophisticated. Used by airlines to basically record the performance of the airplanes. Gives real-time feeding to satellite networks. Still early stages from a revenue perspective. Not quite cash flow positive but getting near so. Has moved up, so let it consolidated a bit.